Active Src mAb

A-CUBE's Clone 28 is a mouse monoclonal antibody which selectively recognizes active-conformation Src family tyrosine kinases. It was discovered in part by A-CUBE Co-founder, Dr. Hisaaki Kawakatsu and colleagues (Kawakatsu, H, et al, "A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase," J Biol Chem. 1996 Mar 8; 271 (10): 5680-5. PMID: 8621432).

Srcs are a family of non-receptor type tyrosine kinases whose activity is greatly increased in many human cancers. Srcs are also involved in a variety of cellular responses and signaling cascades including cell proliferation, differentiation, and migration. These mechanisms are essential in tumor growth and metastasis. Studies have shown that Srcs dynamically change their conformation during activation. They are initially activated by dephosphorylation of a tyrosine residue, Y530 in the C-terminal negative regulatory domain, and further activated by autophosphorylation of another, Y419, in the catalytic domain.

Active-Src specific Clone 28 has a wide range of applications in the field of medical diagnostics, and is a powerful tool in pharmaceutical drug development for patient selection and efficacy evaluation. This antibody is indispensable not only for understanding the mechanism of Src kinase, but also for evaluating the efficacy of Src kinase inhibitors as potential cancer therapeutics. Clone 28 is currently commercialized through Invitrogen.